Editas Medicine Inc (EDIT)

that about 15c better, good start for $5

Editas Medicine shares edge higher after Q4 earnings and revenue top estimatesMarch 9, 2026 9:48 AM
IH Market News
Editas Medicine Inc. (NASDAQ:EDIT) reported fourth-quarter results that came in ahead of analyst expectations, with the gene-editing company posting a smaller-than-expected loss and stronger revenue. The company reported a loss of $0.06 per share, beating the consensus estimate for a $0.23 loss.Revenue totaled $24.74 million, well above the analyst forecast of $8.02 million, although it declined from $30.6 million recorded in the same quarter last year.Following the announcement, shares of the company rose about 2% in pre-market trading.Collaboration and other research and development revenue fell 19% year over year, mainly due to milestone payments recognized under the company’s partnership with Bristol Myers Squibb in the fourth quarter of 2024.“We achieved notable progress in the fourth quarter of 2025 as we advanced our mission and strategy to become a leader in in vivo gene editing,” said Gilmore O’Neill, President and Chief Executive Officer of Editas Medicine.Editas reported a net loss of $5.6 million for the quarter, significantly narrower than the $45.4 million loss recorded in the same period a year earlier.Research and development expenses dropped by $21.2 million to $27.4 million, largely reflecting lower clinical trial and manufacturing costs after the company discontinued its reni-cel program in December 2024.General and administrative expenses also declined, falling $5.0 million to $11.4 million.At the end of the quarter, Editas held $146.6 million in cash and cash equivalents, compared with $269.9 million a year earlier. The company said its current cash reserves are expected to fund operations through the third quarter of 2027.Editas also confirmed it remains on track to submit an IND/CTA application for its lead candidate EDIT-401 by mid-2026 and plans to launch a first-in-human clinical trial later this year in patients with heterozygous familial hypercholesterolemia.In preclinical studies, EDIT-401 achieved an average reduction of more than 90% in LDL cholesterol levels. The company expects to generate initial proof-of-concept data in humans by the end of 2026.Editas Medicine stock price

Original: Editas Medicine shares edge higher after Q4 earnings and revenue top estimates

EDIT-401 achieved LDL-C reductions exceeding 90% within 48 hours of of a single dose. 🥩🍰🍷

yap they needed Craig Venter

New to the board. Hello all.

One of the scientific founders was George Church https://forbetterscience.com/2023/06/26/george-church-colossal-wnker/

frankly speaking this is what happens when four too many Harvard Princeton and MITers scientists crowd meddle with business aspect of science without knowing the feasibility of the therapeutic business academics. well hope they adapt from mistake - promise is still there

WOW how high flying company like KRSP EDIT came to this waist deep muddy hole. Its sad to see not finding partner for EDIT-101 rare eye disease- blindness. Well what next for EDIT in the pipeline after the big lesson - biased arrogancy or genuine marketable efficacious discovery science and technology

Yet another pivot! https://www.globenewswire.com/news-release/2025/09/02/3142475/0/en/Editas-Medicine-Nominates-EDIT-401-an-LDLR-Targeted-Medicine-as-Lead-In-Vivo-Development-Candidate.html

EDIT under $2

EDIT under $2

EDIT, under $2

EDIT, new 52 week low

Turd city today after the morning pop. Whole market in the crapper thanks to Trump and his moronic tariffs. 

EDIT EXPLOSION INTOP CLOSE

EDIT MONSTER

EDIT BEASTING

$EDIT: DoubleBottom confirmed on 100day chart...... now 1.35

This is gonna go to $1.60 from here................... take that to the bank.


GO $EDIT

EDIT, under $2

EDIT, new 52/week low

Another update https://www.globenewswire.com/news-release/2024/12/12/2996508/0/en/Editas-Medicine-Announces-Strategic-Transition-to-in-vivo-Gene-Editing-Company-with-Intent-to-Achieve-Human-Proof-of-Concept-in-Approximately-Two-Years.html

Any target they go after will likely have multiple players (far) ahead them (and some using better delivery and/or editing tech).

EDIT, new 52 week low

OT: In this Dr. Urnov, PhD, laid out the urgent case for major reform in the regulatory appraisal of clinical therapies involving CRISPR gene therapies https://www.liebertpub.com/doi/10.1089/crispr.2024.0082

From the Q&A's, there was no date given on when they will file an IND. They did not answer if other HSC's are targeted. They did not answer what the LNP targeting moiety is. They did not answer how long they will continue to put money into Reni-cel. They did not answer what doses were given. They also said that redosing is being explored (to achieve higher editing efficiency).

I doubt there will be a partner for Reni-cel unless they get a huge part of in vivo as well.

An update https://www.biospace.com/press-releases/editas-medicine-to-host-strategic-update-webinar-to-detail-progress-towards-2024-goals-including-achievement-of-establishing-in-vivo-preclinical-proof-of-concept

https://www.globenewswire.com/news-release/2024/10/21/2966518/0/en/Editas-Medicine-and-Genevant-Sciences-to-Collaborate-to-Develop-Novel-mRNA-LNP-Gene-Editing-Therapeutics.html

EDIT new 52 week low

EDIT new 52 weeknlow

EDIT new 52 low

EDIT new 52 week low

EDIT under $4

EDIT new 52 low

EDIT new 52 week high

EDIT new 52. Week low

EDIT under $6

EDIT under $5

EDIT new 52 week low

EDIT new 52 week low

EDIT new 52 week low

Looking at HbF levels, EDIT-301 appears to achieve slightly higher levels than Casgevy. For total Hb levels, EDIT-301 seems to outperform Casgevy https://finance.yahoo.com/news/editas-medicine-announces-safety-efficacy-070000921.html

However, the ongoing trials and launch are going to be costly, and they aren't working on busulfan free conditioning.

EDIT under $10

(OT): A new AI paper from Princeton and Stanford https://www.biorxiv.org/content/10.1101/2024.04.25.591003v2.full

CRISPR-GPT demonstrated a marked improvement in gene-editing experiments, increasing the accuracy of target gene modifications by up to 30% compared to conventional methods. In validation tests, it achieved a specificity rate exceeding 95%, with a significant reduction in off-targets. The system also reduced the time required to design and plan experiments by approximately 40%, streamlining the workflow for researchers

Dr. Liu moved on with base and prime editing and just left the company to die on the vine.

EDIT under $10

EDIT new 52 week low

EDIT new 52 lo

EDIT new 52 lo

Could be upcoming https://annualmeeting.asgct.org/program/agenda-details?agendaId=25899

If so, CRSP and NTLA have already disclosed preclinical data for in vivo editing.

Does this have any FDA approvals?

No. Plus they are currently focusing on TDT and SCD, both early stage, and both indications becoming more crowed. Also, CRSP should get FDA and EMA approvals for exa-cel in those indications and should have at least five years head start over others.

Will Precision Biosciences be this high or higher?

If the clinical data they present in April/May is good, I expect the SP will increase, but not as high as this. They (DTIL) will also have an upcoming R&D Day (focusing on in vivo programs) mid-year.

How do the two compare?

There are a number of differences. One example, DTIL have yet to show they can do in vivo editing in humans. Another, both have broad plans for in vivo programs, but delivery outside the liver (using current AAVs for many indications) can be problematic.

Does this have any FDA approvals? Will Precision Biosciences be this high or higher? How do the two compare?

PR https://www.globenewswire.com/news-release/2022/05/18/2445810/0/en/Editas-Medicine-Presents-Data-on-SLEEK-Gene-Editing-Technology-at-the-American-Society-of-Gene-and-Cell-Therapy-Annual-Meeting.html

Posters https://www.editasmedicine.com/wp-content/uploads/2022/05/ASGCT2022-EDIT-103-Liu-Presentation.pdf

https://www.editasmedicine.com/wp-content/uploads/2022/05/ASGCT-2022-SLEEK-Zuris.pdf

https://www.editasmedicine.com/wp-content/uploads/2022/05/ASGCT-Kahn-EDIT202-Poster.pdf

https://www.editasmedicine.com/wp-content/uploads/2022/05/ASGCT-Duke-EDIT-101-Immunogenicity-Oral-Presentation.pdf